Navigation Links
Study Provides Evidence That Obesity Leads To A More Aggressive Ovarian Cancer

A new study states that the outcome of a woman diagnosed with ovarian cancer might be affected on whether or not she is obese// .

A new study that is to be published in the October 1, 2006 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a journal of the American Cancer Society, states to have found evidence claiming that obesity leads to more aggressive types of ovarian cancer. The researchers have stated that they have found significant differences in the histological types of epithelial ovarian cancer depending on body mass index (BMI). They also explained that in women with advanced disease, a higher BMI might be associated with a reduced survival rates.

Increasing evidence points to the importance of being obese (BMI greater than 30) and overweight (BMI between 25 and 30) in the development and prognosis of several cancers, including breast, uterine and colorectal. Their relationship to ovarian cancer is less well understood.

Almost one in 60 women will develop ovarian cancer during their lifetimes. Most will be diagnosed with advanced disease and 70 percent will die in five years, making it one of the most lethal cancers. There are several types of ovarian cancer, but tumours that begin from surface cells of the ovary (epithelial cells) are the most common type. A few recent studies have shown that obese patients have a worse outcome. Scientists hypothesize that higher mortality associated with obesity may be caused by more aggressive tumours rather than delays in diagnosis.

Andrew J. Li, M.D. of the Cedars-Sinai Medical Centre and Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute and colleagues reviewed data from 216 women with ovarian cancer to identify relationships between obesity, ovarian cancer, tumour biology, and outcome.

Comparison of obese (35 of 216) and ideal weight (108 of 216) women showed 29 percent of obese women and 10 percent of
'"/>




Page: 1 2

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
(Date:7/9/2008)...aleate (Acepromazine) is on extended backorder fro...nd this preparation into Gourmeds™ (chewable...nsion in the most frequently prescribed strengths....r veterinary use only. , ... -- Commonly prescribed for both cats and dogs, A...
(Date:7/9/2008)...he Maltese healthcare system,will be the focus of ... the,world learn how the island nation,s healthcar...odel for the European Union to follow. Affiliated,...um to discuss the future,of healthcare and informa...tions., Four recognized experts in healthcare and...
(Date:7/9/2008)...mpany Provides Interoperable EHR Solution Capa...ROLLTON, Ga., July 9 /PRNewswire/ -- Greenway Medi...e National Health IT Week,s Capitol Hill,Technolog...ne 9, 2008. The,showcase marked one of the healthc...ime demonstrations of ambulatory software provider...
(Date:7/9/2008)...r Summer, LAUREL, Miss., July 9 /PRNewswire/ -- W...popular parking place for TV-watchers, Sanderson F...mer program to encourage,families to get healthy b..., Studies show that over the course of a year, ch... school or participating in any activity other,tha...
Breaking Medicine News(10 mins):Health News: Wedgewood Pharmacy Responds to Acepromazine Maleate Drug Shortage 2Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 2Health News:ACS Forum to Showcase Innovative Healthcare Model for European Union 3Health News:Greenway Medical Technologies Leads Ambulatory Interoperability Exchange 2Health News:Greenway Medical Technologies Leads Ambulatory Interoperability Exchange 3Health News:Greenway Medical Technologies Leads Ambulatory Interoperability Exchange 4Health News:Sanderson Farms Launches New Summer Program Encouraging Families to Get Healthy 2
...creased by 12% in six years, according to the char...are now diagnosed with the disease, 3,000 of those...elanomas in men is that they tend to occur more co...they are often on the lower leg and more noticeabl...
...nancy can increase a mother's risk of having a hyp...ere very anxious// in the last three months of pre.... Lead researcher Professor Vivette Glover, of Im... only applied to women who had extreme anxiety, an...
...n somebody is likely to have an epileptic seizure....enly and without warning and can lead to disabilit... la Pitie-Salpetriere, Paris, believe it may be po...res by carrying out an electroencephalogram (EEG)....
...than 100 years. And while most of the popular reme... the use of aspirin has increased. This powerful p...nt blood clots, and even reduce the risk of heart ...35 years since aspirin's potent anti-clotting effe...
Other Medicine News:
(Date:7/8/2008)...- McGraw-Hill Professional, a leading,global provi...d medical,communities, today announced the additio...its comprehensive online pharmacy education,resour... ). Through an alliance with,Doctor Evidence, deve...ical,studies, AccessPharmacy now provides in-conte...
(Date:7/7/2008)... Includes ANA598 and ANA773 Acting via In... Conference Call Today at 2:00 PM... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ann...ation of the Toll-Like Receptor-7 (TLR7) mechanism...n preclinical pharmacology testing,and the results...
(Date:7/7/2008)...-- OrbusNeich today announced that data,presented ...e Society of,Interventional Cardiology demonstrate... outcomes when compared to drug-eluting stents., ...principal,investigator and a professor with the Fe...ology, Department of Clinical Medicine and Cardiov...
(Date:7/6/2008)...ing Authorization Application currently ...uly 7 /- Cell Therapeutics,...the publication of results from its,randomized pha...glumex,CT-2103) with gemcitabine or vinorelbine f...tients with previously untreated non-small cell,lu...
Breaking Medicine Technology:McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5APIC launches first national C difficile prevalence study 14826 1APIC launches first national C difficile prevalence study 14826 2Cato Study Finds Iran a Surprising Model for Kidney Markets 14823 1Cato Study Finds Iran a Surprising Model for Kidney Markets 14823 2NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 1573 1NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 1573 2Subterfuge counter surveillance and assassination 3A The bodys fight with cervical cancer 2560 1Subterfuge counter surveillance and assassination 3A The bodys fight with cervical cancer 2560 2
...BOULDER, Colo.--(BUSINESS WIRE)--Jul 5, 2007 - Arr...hat its Chief Executive Officer,Robert E. Conway,...rowth Conference on July 10 in New York City. The ... through a webcast on the,Array BioPharma website....ng Growth Conference,Presenter: Robert E. Co...
... REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, ...nomics Ltd , a leading microRNA,company, announced...esident, will present at CE Unterberg, Towbin Emer...uly 10, at 11:00 am EST at,the Mandarin Oriental H...esentation will be available on,the "Investors" se...
Other Medicine Technology:Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin,Emerging Growth Opportunities Conference 2
The BARDEX I.C. Catheter represents Bard's newest technology in providing protection against NUTI.
Used to provide bladder drainage by percutaneous placement of a Malecot catheter. Supplied sterile in peel-open packages. Intended for one-time use.
Surgisis ES is designed to provide enhanced strength for intraoperative applications. Supplied sterile in peel-open packages. Intended for single patient, one-time use.
Stratasis Urethral Sling is intended for implantation to reinforce soft tissues where weakness exists. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: